Chem-Tech, Ltd. lacked adequate investigations and clean equipment for its OTC drug.
What happened
FDA inspected Chem-Tech’s drug manufacturing facility in Pleasantville, IA, from September 17 to 20, 2024. It found inadequate investigations of out-of-specification (OOS) assay results, unsanitary mixing and filling areas, and inadequate quality unit procedures, all cited as current good manufacturing practice (CGMP) violations. FDA also said Chem-Tech’s October 11, 2024, response lacked supporting documentation and evidence of corrective actions.
What FDA found
Chem-Tech did not thoroughly investigate out-of-specification assay results or unexplained batch failures, did not determine root causes, and released reworked batches without adequate corrective and preventive actions (CAPA).
21 CFR 211.192Chem-Tech lacked scientifically supported mixing process validation and finished-product hold-time studies; its validation covered only filling and hold times were changed without supporting data.
21 CFR 211.110(a)Chem-Tech did not keep equipment clean and maintained; investigators saw dirt and a dead insect on a mixing tank lid, leftover product and discoloration in the tank, and no validated cleaning procedure.
21 CFR 211.67(a) and (b)Chem-Tech lacked a preventive maintenance program with procedures, and the meter used to add potable water to the drug product had never been calibrated.
21 CFR 211.67(a) and (b)Chem-Tech’s quality unit lacked procedures for GMP training, OOS handling, and change management, and its deviation and complaint procedures were inadequate.
21 CFR 211.22(d)
What FDA wants
FDA asks Chem-Tech to respond in writing within 15 working days with what it has done to correct the violations and prevent recurrence, and if it cannot finish, to give reasons and a completion schedule. If it plans to resume drug manufacturing, it must notify FDA and provide a summary of remediations and CAPA.
Who should pay attention
- brands that buy OTC drugs from contract manufacturers
- contract manufacturers with shared mixing and filling equipment
- quality teams handling OOS investigations, cleaning validation, and complaints
This is a summary. Read the original letter on fda.gov.